Thrombosis Research
Volume 126, Issue 2 , Pages 113-118 , August 2010

Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy

Received 26 February 2010 ,Revised 2 April 2010 ,Accepted 13 May 2010.

References 

  1. Yarnell JW, Patterson CC, Sweetnam PM, Lowe GD. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies.[see comment]. Eur Heart J. 2004;25:1049–1056
  2. Brown DW, Ford ES, Giles WH, Croft JB, Balluz LS, Mokdad AH. Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II Mortality Study, 1976-1992. Ann Epidemiol. 2004;14:425–430
  3. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. European Collaboration on Low-Dose Aspirin in Polycythemia V: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446–2452
  4. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310–2313
  5. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26:2732–2736
  6. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–4907
  7. Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007;25:3313–3320
  8. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001;92:2399–2405
  9. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations–a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23:6240–6248
  10. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12:1423–1432
  11. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007;25:1562–1569
  12. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA : J Am Med Asso. 2005;293:715–722
  13. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–815
  14. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemostasis : JTH. 2007;5:632–634
  15. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488
  16. Prandoni P, Trujillo-Santos J, Surico T, Dalla Valle F, Piccioli A, Monreal M. Investigators R: Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry. Haematologica. 2008;93:1432–1434
  17. Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica. 2008;93:273–278
  18. Kuderer NM, Khorana AA, Francis CW, Culakova E, Ortel TL, Falanga A, et al. Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy. In: Blood (ASH Annual Meeting Abstracts). vol. 112:2008;[abstract 172]
  19. Ay C, Chiriac AL, Dunkler D, Vormittag R, Simanek R, Quehenberger P, et al. Biomarkers improve the risk scoring model for prediction of cancer-associated thrombosis. J Thromb Haemost. 2009;7:
  20. Price L, Nguyen M, Picozzi R, Kozarek R. In: 2010;
  21. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2008;7:613–615
  22. Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006;107:1793–1800
  23. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002;22:913–922
  24. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286–1292
  25. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1998;18:1199–1202
  26. Herrmann FR, Safran C, Levkoff SE, Minaker KL. Serum albumin level on admission as a predictor of death, length of stay, and readmission. Arch Intern Med. 1992;152:125–130
  27. McCluskey A, Thomas AN, Bowles BJ, Kishen R. The prognostic value of serial measurements of serum albumin concentration in patients admitted to an intensive care unit. Anaesthesia. 1996;51:724–727
  28. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–967
  29. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol. 2008;24:320–327
  30. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood. 2009;114:759–763
  31. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97:978–985
  32. Lwaleed BA, Francis JL, Chisholm M. Tissue factor assays as diagnostic tools for cancer? Correlation between urinary and monocyte tissue factor activity. J Hematother Stem Cell Res. 1999;8:659–668
  33. Lwaleed BA, Chisholm M, Francis JL. The significance of measuring monocyte tissue factor activity in patients with breast and colorectal cancer. Br J Cancer. 1999;80:279–285
  34. Lwaleed BA, Francis JL, Chisholm M. Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression. BJU Int. 1999;83:476–482
  35. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS). In: Blood. 2008;
  36. di Carlo E, Iezzi M, Pannellini T, Zaccardi F, Modesti A, Forni G, et al. Neutrophils in anti-cancer immunological strategies: old players in new games. J Hematother Stem Cell Res. 2001;10:739–748
  37. Coussens LM, Werb Z. Inflammation and cancer.[see comment]. Nature. 2002;420:860–867
  38. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?[see comment]. Lancet. 2001;357:539–545
  39. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315–322
  40. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–727
  41. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt). 2003;17:126–135[139; discussion 139-144]

PII: S0049-3848(10)00295-1

doi: 10.1016/j.thromres.2010.05.012

Thrombosis Research
Volume 126, Issue 2 , Pages 113-118 , August 2010

Article Tools

* Image Usage & Resolution